PACTR201605001602542
Recruiting
未知
A Demonstration Project of Antiretroviral-based HIV-1 Prevention Among High-risk HIV-1 Serodiscordant Couples in Nigeria
ational Agency for the Control of AIDS0 sites600 target enrollmentApril 24, 2016
ConditionsHIV/AIDS
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- HIV/AIDS
- Sponsor
- ational Agency for the Control of AIDS
- Enrollment
- 600
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •For heterosexual couples:
- •1\). Sexually active (defined as having had vaginal intercourse at least 6 times in the previous three months)
- •2\). Willing to enter the study as a couple and intending to remain as a couple for the next 12 months
- •3\). Has not been on PrEP medication prior to enrollment in study
- •For HIV\-1 uninfected members of the couple (partner participants):
- •1\). Able and willing to provide written informed consent
- •2\). HIV\-1 uninfected based on negative HIV\-1 rapid tests, both at study screening and at the enrolment visit
- •3\).Adequate renal function, defined by normal creatinine levels and estimated creatinine clearance ¿60 mL/min
- •4\). Not currently pregnant or breastfeeding
- •5\).Not currently enrolled in an HIV\-1 prevention clinical trial
Exclusion Criteria
- •1\. Currently on ART and virally suppressed
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 1
Immunological and Virucidal effect of Amrita Tablet for Prevention of HIV AIDSCTRI/2024/01/062079Satyananda yoga and Ayurveda Research institute Motihari
Completed
Not Applicable
A clinical trial of R-CHOP with antiretroviral therapy for newly diagnosed CD20 positive AIDS-related non-Hodgkin lymphomaewly diagnosed CD20 positive AIDS-related non-Hodgkin lymphomaJPRN-UMIN000001452AIDS Clinical Center42
Completed
Not Applicable
Development of the new HIV testing system and surveillance of HIV incidence in MSMHIV infectionJPRN-UMIN000018699AIDS Clinical Center, National Center for Global Health and Medicine1,000
Active, not recruiting
Phase 1
Initiation of first-line antiretroviral treatment with TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the first clinical contact in France: Trial IMEA 055 – FASTHIV positive age > 18 years -newly diagnosed HIV-infected individual evidenced by any tests -antiretroviral-treatment naive -negative urine pregnancy test -willing to sign an informed written consent– -regular health insurance -willing to provide two distinct contact information (telephone number and/or email) in order to be easily reached if needed between Day 0 and Day 7Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2019-000812-27-FRIMEA110
Completed
Not Applicable
A randomised controlled trial of mobile phones to influence adherence to first line antiretroviral treatment among human immunodeficiency virus (HIV) infected patients in South IndiaHuman immunodeficiency virus (HIV)Infections and InfestationsISRCTN79261738European Union (EU) (Belgium)600